AngioDynamics Inc. (NASDAQ:ANGO) reached a new 52-week high during trading on Friday . The company traded as high as $16.42 and last traded at $16.21, with a volume of 265,976 shares trading hands. The stock had previously closed at $16.03.

A number of research firms recently commented on ANGO. Zacks Investment Research raised shares of AngioDynamics from a “sell” rating to a “hold” rating in a research report on Wednesday, June 8th. Canaccord Genuity cut shares of AngioDynamics from a “buy” rating to a “hold” rating and decreased their price target for the stock from $14.50 to $13.00 in a report on Tuesday, April 5th. KeyCorp decreased their price target on shares of AngioDynamics from $17.00 to $16.00 and set an “overweight” rating for the company in a report on Friday, April 8th. Finally, Piper Jaffray Cos. assumed coverage on shares of AngioDynamics in a report on Friday, April 8th. They issued a “neutral” rating and a $12.00 price target for the company. Five research analysts have rated the stock with a hold rating and one has issued a buy rating to the company’s stock. The stock presently has a consensus rating of “Hold” and an average target price of $14.10.

The firm’s market cap is $586.83 million. The firm has a 50 day moving average price of $13.61 and a 200-day moving average price of $12.00.

AngioDynamics (NASDAQ:ANGO) last announced its quarterly earnings data on Wednesday, July 13th. The company reported $0.19 earnings per share for the quarter, beating analysts’ consensus estimates of $0.16 by $0.03. During the same quarter last year, the firm posted $0.14 EPS. The business earned $93.40 million during the quarter, compared to analyst estimates of $88.64 million. The company’s revenue for the quarter was up 2.8% on a year-over-year basis. Equities research analysts forecast that AngioDynamics Inc. will post $0.65 EPS for the current fiscal year.

In other AngioDynamics news, VP Charles R. Greiner sold 3,508 shares of the business’s stock in a transaction that occurred on Friday, May 6th. The shares were sold at an average price of $12.31, for a total transaction of $43,183.48. Following the completion of the transaction, the vice president now owns 20,910 shares in the company, valued at approximately $257,402.10. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, SVP Stephen A. Trowbridge sold 12,940 shares of the business’s stock in a transaction that occurred on Monday, April 25th. The stock was sold at an average price of $12.30, for a total transaction of $159,162.00. Following the transaction, the senior vice president now owns 32,469 shares of the company’s stock, valued at approximately $399,368.70. The disclosure for this sale can be found here.

A number of hedge funds and institutional investors have recently bought and sold shares of the company. Morgan Stanley boosted its position in AngioDynamics by 6.2% in the fourth quarter. Morgan Stanley now owns 98,634 shares of the company’s stock valued at $1,198,000 after buying an additional 5,728 shares during the period. Lapides Asset Management LLC boosted its position in AngioDynamics by 1.2% in the fourth quarter. Lapides Asset Management LLC now owns 700,500 shares of the company’s stock valued at $8,504,000 after buying an additional 8,400 shares during the period. Nationwide Fund Advisors boosted its position in AngioDynamics by 252.9% in the fourth quarter. Nationwide Fund Advisors now owns 88,374 shares of the company’s stock valued at $1,073,000 after buying an additional 63,332 shares during the period. Royce & Associates LLC boosted its position in AngioDynamics by 19.0% in the fourth quarter. Royce & Associates LLC now owns 640,801 shares of the company’s stock valued at $7,779,000 after buying an additional 102,098 shares during the period. Finally, Whitebox Advisors LLC purchased a new position in AngioDynamics during the fourth quarter valued at approximately $1,384,000.

AngioDynamics, Inc designs, manufactures and sells a range of medical, surgical and diagnostic devices used by professional healthcare providers for vascular access, for the treatment of peripheral vascular disease, and for use in oncology and surgical settings. The Company’s devices are used in minimally invasive, image-guided procedures.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.